Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 10, pp 3209–3215 | Cite as

Genetic Testing Today

  • David EuhusEmail author
Breast Oncology

Abstract

Background

The commercial introduction of next-generation sequencing has made it possible to test for mutations in all known or suspected breast cancer predisposition genes in one panel, at one time, for about the same cost as a BRCA gene test. Clinicians are increasingly presented with the challenge of advising patients with mutations in rare breast cancer predisposition genes.

Methods

Literature review and personal experience with panel tests.

Results

Panel tests are more likely to identify a variant of uncertain clinical significance than a deleterious mutation. In addition, not all of the genes included in panel tests are unequivocally linked to increased breast cancer risk, and for most genes the penetrance is highly variable, making it difficult to translate a specific mutation into an absolute breast cancer risk. The three-generation cancer family history should be used to select truly high-risk families for panel testing, and then referred to again when the results are received in order to guide risk-management decisions. Knowing a breast cancer patient’s mutation status can influence decisions about local–regional and systemic therapy, but turnaround times for many tests are still too long to incorporate them into the initial evaluation of a new breast cancer.

Conclusion

The commercialization of next-generation sequencing has the potential to greatly enhance the identification and management of individuals with an inherited predisposition to breast cancer. A period of uncertainty is anticipated before the full potential of this new technology is realized.

Keywords

Breast Cancer Breast Cancer Risk Mutation Carrier Deleterious Mutation Panel Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

DISCLOSURE

None.

References

  1. 1.
    Lebert H. Traite Pratique des Maladies Cancereuses. Paris: Librarie de L’Academie Nationale de Medecine;1851:134–135.Google Scholar
  2. 2.
    Broca P. Traité des tumeurs. Paris: P. Asselin; 1866: pp. 150–152.Google Scholar
  3. 3.
    Mendel G. Versuche über Pflanzenhybriden Verh Naturforsch Ver Brünn. 1865;4:3–47.Google Scholar
  4. 4.
    Miescher F. Ueber die chemische Zusammensetzung der Eiterzellen. Med Chem Unters. 1871;4:441–460.Google Scholar
  5. 5.
    Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 1944;79:137–158.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239(4839):487–491.PubMedCrossRefGoogle Scholar
  7. 7.
    Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–1690.PubMedCrossRefGoogle Scholar
  8. 8.
    Solomon E, Ledbetter DH. Report of the Committee on the Genetic Constitution of Chromosome 17. Cytogenet Cell Genet. 1991;58:686–738.CrossRefGoogle Scholar
  9. 9.
    Schmutz J, Wheeler J, Grimwood J, et al. Quality assessment of the human genome sequence. Nature. 2004;429(6990):365–368.PubMedCrossRefGoogle Scholar
  10. 10.
    Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088–2090.PubMedCrossRefGoogle Scholar
  12. 12.
    Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:7897–7892.CrossRefGoogle Scholar
  13. 13.
    Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:333–337.PubMedCrossRefGoogle Scholar
  14. 14.
    Baker SG, Lichtenstein P, Kaprio J, Holm N. Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. Biometrics. 2005;61(1):55–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Locatelli I, Lichtenstein P, Yashin AI. The heritability of breast cancer: a Bayesian correlated frailty model applied to Swedish twins data. Twin Res. 2004;7(2):182–191.PubMedCrossRefGoogle Scholar
  16. 16.
    Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev. 2001;10(7):733–741.PubMedGoogle Scholar
  18. 18.
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer. 1994;73(3):643–651.PubMedCrossRefGoogle Scholar
  19. 19.
    Gracia-Aznarez FJ, Fernandez V, Pita G, et al. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PloS One. 2013;8(2):e55681.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143–2153.PubMedCrossRefGoogle Scholar
  21. 21.
    Litim N, Labrie Y, Desjardins S, et al. Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population. Mole Oncol. 2013;7(1):85–100.CrossRefGoogle Scholar
  22. 22.
    Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410–414.PubMedCrossRefGoogle Scholar
  23. 23.
    Snape K, Eccles D, Evans C, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012;44(5):475–476.PubMedCrossRefGoogle Scholar
  24. 24.
    Panchal S, Bordeleau L, Poll A, et al. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet. 2010;77(3):273–279.PubMedCrossRefGoogle Scholar
  25. 25.
    Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89:227–238.PubMedCrossRefGoogle Scholar
  26. 26.
    Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76–83.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors [published erratum appears in Stat Med. 2005;24(1):156]. Stat Med. 2004;23(7):1111–1130.PubMedCrossRefGoogle Scholar
  28. 28.
    Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med. 2014;16(5):407–412.PubMedCrossRefGoogle Scholar
  29. 29.
    Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151–161.PubMedCrossRefGoogle Scholar
  30. 30.
    Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29(28):3747–3752.PubMedCrossRefGoogle Scholar
  31. 31.
    Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–1135.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Byrd PJ, Srinivasan V, Last JI, et al. Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia. Br J Cancer. 2012;106(2):262–268.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Tanteles GA, Murray RJ, Mills J, et al. Variation in telangiectasia predisposing genes is associated with overall radiation toxicity. Int J Radiat Oncol Biol Phys. 2012;84(4):1031–1036.PubMedCrossRefGoogle Scholar
  34. 34.
    Pierce LJ, Haffty BG. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol. 2011;21(1):43–50.PubMedCrossRefGoogle Scholar
  35. 35.
    National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology v.1.2014. Vol 1. Fort Washington (PA): NCCN; 2014.Google Scholar
  36. 36.
    King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646.PubMedCrossRefGoogle Scholar
  37. 37.
    Kotsopoulos J, Olopado OI, Ghadirian P, et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7(5):R833–843.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography [published erratum appears in CA Cancer J Clin. 2007;57(3):185]. CA Cancer J Clin. 2010;57(2):75–89.CrossRefGoogle Scholar
  39. 39.
    Gronwald J, Pijpe A, Byrski T, et al. Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat. 2008;112(3):581–584.PubMedCrossRefGoogle Scholar
  40. 40.
    Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst. 2009;101(3):205–209.CrossRefGoogle Scholar
  42. 42.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388.PubMedCrossRefGoogle Scholar
  43. 43.
    Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–2391.PubMedCrossRefGoogle Scholar
  45. 45.
    Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–1048.PubMedCrossRefGoogle Scholar
  46. 46.
    Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091–3099.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281–2284.PubMedCrossRefGoogle Scholar
  48. 48.
    Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–975.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–1337.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Sitzmann JV, Wiebke EA. Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer. JAMA Surg. 2013;148(3):285–291; discussion 291.PubMedCrossRefGoogle Scholar
  52. 52.
    Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335–3344.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–164.PubMedCrossRefGoogle Scholar
  54. 54.
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84.PubMedCrossRefGoogle Scholar
  55. 55.
    Rusby JE, Smith BL, Gui GP. Nipple-sparing mastectomy. Br J Surg. 2010;97(3):305–316.PubMedCrossRefGoogle Scholar
  56. 56.
    Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43(2):238–257.PubMedCrossRefGoogle Scholar
  57. 57.
    Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121(2):389–398.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135–142.PubMedCrossRefGoogle Scholar
  59. 59.
    Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Wysocki PJ, Korski K, Lamperska K, Zaluski J, Mackiewicz A. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit. 2008;14(7):SC7-10.PubMedGoogle Scholar
  61. 61.
    Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108(2):289–296.PubMedCrossRefGoogle Scholar
  62. 62.
    Stordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007;33:688–703.PubMedCrossRefGoogle Scholar
  63. 63.
    Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller Z, Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22:1169–1173.PubMedGoogle Scholar
  64. 64.
    Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375–379.PubMedCrossRefGoogle Scholar
  65. 65.
    Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–363.PubMedCrossRefGoogle Scholar
  66. 66.
    Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–775.PubMedCrossRefGoogle Scholar
  67. 67.
    Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.PubMedCrossRefGoogle Scholar
  68. 68.
    Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–244.PubMedCrossRefGoogle Scholar
  69. 69.
    Min A, Im SA, Yoon YK, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther. 2013;12(6):865–877.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  1. 1.Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations